Breaking News, Collaborations & Alliances

Junshi Biosciences, Rxilient Biotech Partner Develop Toripalimab in Southeast Asia

The two parties plan to collaborate to introduce more high-quality innovative drugs into Southeast Asian markets to achieve joint and long-term development.

Junshi Biosciences Co., Ltd and Rxilient Biotech entered into a collaboration for the development and commercialization of the anti-PD-1 monoclonal antibody drug, toripalimab, through joint venture in 9 Southeast Asian nations, including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam. “This extensive collaboration with Rxilient Biotech in Southeast Asia is a vital step for Junshi Biosciences as we strive to expand our global commercialization netw...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters